Because "every product is related to the life of a patient, so the quality of each product is related to the life of the enterprise." Therefore, at Weigao, the quality management concept of "10000-1=0" It has been deeply rooted in people's hearts. They deeply understand the connotation of the service concept of "quality first, customer satisfaction". They regard quality as the most critical guarantee for establishing a brand, and propose "requiring quality from management, seeking brand from quality, seeking market from brand, and seeking benefits from market." In order to implement quality management, Weigao Group Company, branches (subsidiaries), and workshops are supervised at all levels, and workshops, teams, and processes are deployed to strengthen responsibilities and strictly manage. Everyone has the right to veto; when raw materials enter the company, We all have veto power in warehouse, production and delivery, and resolutely prevent unqualified raw materials from entering the factory and unqualified products from leaving the factory. Once, a workshop quality inspector discovered during a random inspection that a blood bag was slightly insufficient, and this batch of products was to be delivered to the customer the next day. But they immediately organized staff to work overtime all night to reweigh the 400 boxes of blood bags that had been packed. It turned out that the only problem with the weighing was this blood bag. The person in charge of the company said that in quality management, even one ten thousandth possible error cannot be ignored.
In order to improve product quality, Weigao Group has also introduced advanced medical needle production lines, orthopedic material production lines, medical catheter production lines, and prefilled syringe production lines from Japan, South Korea, the United States, the Netherlands, Singapore and other countries. Production equipment, these highly automated equipment provide reliable guarantee for the standardization of production and quality control. In addition, Weigao Group has also built a testing institution that has reached the international advanced level. The testing center has imported advanced testing instruments such as liquid chromatographs and gas chromatographs from Japan and Switzerland. This is the only testing institution in China's medical device industry that is accredited by the National Laboratory Accreditation Board. The test reports they issue have international validity and can be recognized by other countries in the Asia-Pacific region and even the world.
It is these strict quality management and assurance systems that provide a strong guarantee for the production of high-quality products. In 1998, Weigao Group was the first in the industry to pass the ISO9000 quality management system certification. In 1999, it was the first in the industry to pass the EU CE standard certification. The production of blood transfusion equipment products passed the GMP certification. In June 2005, Weigao Group's "Jierui" trademark was recognized by the State Administration for Industry and Commerce as the first Chinese well-known trademark in China's medical device industry; in September 2006, "Jierui" brand disposable infusion medical device series products Won the title of China Famous Brand, "Jierui" brand products are designated as national inspection-free products. Today, "Jierui" has not only won widespread praise and established a good image among users in 30 provinces, municipalities, and autonomous regions across the country, but is also sold well in 30 countries and regions including the United States, Brazil, Germany, Russia, South Africa, and India. The cardiac drug stent is a high-tech product for the treatment of coronary heart disease. It delivers the drug stent to the diseased site through interventional surgery to support narrow blood vessels. For a long time, China's cardiac drug stent market has been dominated by large European and American companies. They have mastered the most critical technology, and their products are extremely expensive and unaffordable for ordinary patients. After arduous research, Weigao Group has developed a cardiac drug-coated stent with independent intellectual property rights, creatively changing the medication from spray coating to coating. All technical indicators have reached the international advanced level, and the price is lower than that of foreign products. About 30%. The advent of this product broke the long-term monopoly of strong foreign companies on China's cardiac drug stent market, freed our country from being controlled by others in the use of this product, and greatly reduced the burden on patients.
In Weigao, there are many products with independent intellectual property rights, such as cardiac drug-coated stents. Prefilled syringe is a high-grade pharmaceutical packaging material. It puts liquid medicine directly into the syringe for storage. It is simple and convenient to use. At the same time, the syringe itself has good sealing properties and the medicine can be stored for a long time. This product has been widely used in developed countries such as Europe and the United States, but it has just begun to be used in our country, and it is all monopolized by foreign companies, and the price remains high. In November 2005, Weigao Group developed a prefilled syringe with independent intellectual property rights, which was more than 10% cheaper than foreign products.
Relying on independent innovation to adjust product structure, seize the technological commanding heights, and adapt to the fiercely competitive market are important strategic policies of Weigao Group.
In order to keep abreast of the progress of current technology and track the latest developments in domestic and foreign technology, the company has strengthened its contacts with relevant scientific research institutes, and has successively cooperated with Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences, Dalian Institute of Physics and Chemistry, Beijing 301 Hospital, Southwest Hospital of the Third Military Medical University, etc. In cooperation with institutes, 9 R&D centers have been established in different places and have an industry-leading innovative R&D platform. Weigao also attaches great importance to the construction of a talent team and investment in product research and development. The company spends more than 5% of its sales revenue on new product research and development every year; the company specially hires 6 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering as consultants; it has established a The postdoctoral scientific research workstation has 9 doctors and postdocs; it has established a talent supply and demand relationship with Qingdao University of Science and Technology, Sichuan University and other domestic institutions of higher learning to attract talents to join; it has directional training of industrialization implementation talents at Shanghai Vocational University, forming a technology research and development, product center Implement a one-stop talent introduction and training pattern for trial and industrialization.
In recent years, Weigao Group has also continuously improved its technological innovation system, established four-level technological innovation platforms at the national, provincial, municipal and enterprise levels, and strengthened industry-university-research cooperation. Weigao Group has further integrated innovation institutions, strengthened the management of new product research and development, and formulated a "R&D Management System" to standardize the management of the entire process from product establishment to acceptance of R&D products. The company holds a monthly R&D project work report meeting to rationally allocate R&D resources, strengthen planning control, and rationally use R&D funds. Disposable hollow fiber plasma separators, A-type blood takers, spring self-destructing safety syringes, medical light-proof plastics... Today, Weigao Group has more than 100 patented products, 21 of which have reached the domestic leading level. The strong ability of independent innovation and the continuously rising level of independent research and development have given Weigao the right to speak in the international market and the initiative for development. In 2005, Weigao Group actively contacted a medical device company in the United States. Through negotiation, the two parties reached a cooperative production and sales agreement on the basis of mutual benefit. The company's products will be sold as a labeling agent in the United States. This is just one of the measures taken by Weigao Group to build a Chinese national brand in the international market. Facing the market environment of global economic integration, Weigao people understand that if an enterprise does not integrate into the international market, its brand promotion will be limited and its development will be hindered. Without occupying a place in the international market, it is difficult to establish a national brand. Therefore, in the late 1990s, Weigao people began to carry out international marketing and actively entered the international market. Some merchants and users from more than 20 countries and regions, including Germany, the United Kingdom, Russia, Belgium, the United States, Malaysia, and Brazil, keenly discovered the growth advantages of the "Jierui" brand and ordered "Jierui" products one after another.
After 2000, Weigao Group further increased the protection of its brands at home and abroad, bringing trademark protection in line with international standards. Domestically, Weigao Group has started to use the "Jierui" trademark since its establishment, and its trademark protection categories have reached 31 types; internationally, it has been used in 20 countries including Cuba, Germany, Egypt, France, Russia, Vietnam, the United Kingdom, and Turkey. The state's trademark registration has enabled the sales of the "Jierui" brand abroad to enter a stage of rapid growth.
In 2001, Weigao Group formulated a new product export strategy, expanding its original focus on the Southeast Asian market to the global market, focusing on the European and African markets, and established a professional export sales team. They have stabilized major customers, optimized market resources, strengthened sales in the Middle East, Asia and other markets, and used existing customer relationship channels to drive sales to the European and American markets. Through a business relationship with an Iranian customer, the group won an order for nearly 30 million products from a Bulgarian company; it seized the opportunities of economic development in Russia and other CIS countries, increased the company's sales in the Russian market, radiated to neighboring countries, and extensively expanded into Northern Europe. market. At the same time, they also carry out various forms of cooperation with foreign companies, using labeling production or agency sales to expand overseas trade. Strengthen the international standards of enterprises. In addition to passing the EU CE certification, we are also working hard on the US FDA certification. Products such as syringes, syringes, and feeders have passed the 510K license issued by the FDA, thus clearing the way for the products to be successfully exported to the United States.
On February 27, 2004, Weigao Group Medical Polymer Products Co., Ltd. was successfully listed on the Hong Kong GEM. It not only provided funds for the development and production of high-tech products, but also achieved various benefits through listing. Integrating with international standards has enhanced the international reputation of enterprises and products. Today, Weigao Group, a national brand, is moving towards the international first-class level.